Mind boggling really - it might take years of investing in small cap biotech to fully comprehend this, and truely put things into perspective.
University of Washington (a USA top 5 cancer hospital) tweeting (see very below) suggesting this paxalisib plus radiation FDA study - is one of their important trials. They would be conducting dozens of other trials - many in radiation. Its not as if this trial is for some rare cancer - buts its paxalisib to make radiation work better.
A potential worth therefore of many billions of dollar - the words in the tweet are not mine.... or even the company Kazia, but from this esteemed university, talking of paxalisib.
You might say with some reasonable conviction - that paxalisib is in the top 2 or 3 - most valuable cancer drugs in development.
------------------------------------------
UW RadOnc Metastasis & Developmental Therapeutics
@RadOncMTD
University of Washington Radiation Oncology Metastatic Disease and Developmental Therapeutics - new to Twitter, not great at it, good vibes only
Seattle, WAJoined June 2023
95 Following
21 Followers
Not followed by anyone you’re following
Tweets
Replies
Media
Likes
UW RadOnc Metastasis & Developmental Therapeutics’s Tweets
Pinned
UW RadOnc Metastasis & Developmental Therapeutics
@RadOncMTD
·
Jul 22
One of our important trials in the news #PI3K #btsm
@TargetedOnc
@MSK_RadOnc
@MiamiCancerInst
targetedonc.com
FDA Awards Fast Track Designation to Paxalisib With Radiation for Brain Metastases
An investigation of treatment with concurrent paxalisib and whole brain radiotherapy is underway in a phase 1 clinical
